<DOC>
	<DOCNO>NCT00637000</DOCNO>
	<brief_summary>The purpose study compare presence , degree , time course profile opioid withdrawal symptom associate induction onto new formulation buprenorphine buprenorphine/naloxone person active opioid dependence . The primary outcome measure severity withdrawal symptom measure use Clinical Opiate Withdrawal Scale ( COWS ) . The primary study hypothesis neither drug formulation precipitate opioid withdrawal syndrome .</brief_summary>
	<brief_title>Induction Opioid-Dependent Individuals Onto Buprenorphine Buprenorphine/Naloxone</brief_title>
	<detailed_description>Buprenorphine sublingual buccal soluble film develop used indication buprenorphine dose range Subutex Suboxone sublingual tablet treatment opioid dependence . However , film administer sublingual route evaluate study . The soluble film dosage expect provide follow enhancement potential advantage current Subutex Suboxone product : - Mitigation unintentional pediatric exposure provide child-resistant packaging unit dose format . - Improvement subject convenience compliance ensure rapid disintegration . - Protection diversion provide dosage form difficult subject remove sublingual buccal mucosa administration . This provide assurance caregiver dose actually take appropriately supervised setting . - Provision unit dose product format hospital institutional use . - Decreased product damage shipping compare Subutex Suboxone tablet .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Subject must : Provide write informed consent . Have Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) diagnosis opioid dependence . Be male female , 18 65 year age , inclusive . If female , negative pregnancy test screen agree use acceptable method birth control . Subjects must : Have participate experimental drug device study within last 30 day . Be currently ( past 30 day start screen ) engage opioid agonist , opioid partial agonist , opioid antagonist treatment . If female , breast feeding lactating . Have medical condition opinion physician investigator would preclude subject complete study . Have clinically significant nonsubstance use psychiatric disorder ( e.g. , schizophrenia ) . Have current suicidal ideation . Have Mini Mental Status Exam score less 24 . Have physical dependence alcohol . Have physical dependence sedativehypnotics . Have active aphthous stomatitis . Have active oral herpes . Need ongoing prescription medication interact P450 3A4 ( member cytochrome P450 superfamily enzymes ) system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Opioid dependence</keyword>
	<keyword>Opioid withdrawal symptom</keyword>
</DOC>